Metsera Inc
MTSR51.900USD
+0.200+0.39%
收盤 10/03, 16:00（美東）報價延遲15分鐘
5.44B總市值
虧損本益比TTM
關於 Metsera Inc 公司
Metsera, Inc. 是一家臨牀階段的生物技術公司，致力於開發注射和口服營養刺激激素 (NuSH) 類似物肽，用於治療肥胖、超重和相關疾病。該公司利用其專有的 MINT NuSH 類似物肽庫以及其脂質優化半衰期增強 (HALO) 半衰期延長平臺和其 MOMENTUM 口服 NuSH 類似物肽遞送平臺來提供高度差異化的產品候選物。其產品線包括 MET-097i、MET-233i / MET-233i + MET-097i 和 MET-224o。其先進產品候選物 MET-097i 是一種完全偏向的、每月一次的、皮下注射的超長效 GLP-1 RA。MET-233i 是一種皮下注射的超長效胰島澱粉樣肽類似物，具有增強的溶解性和與其他 NuSH 類似物肽的混溶性。 MET-224o 是一種口服、完全偏向的超長效 GLP-1 RA。該公司的產品線還包括 MET-002o、MET-AMYo、MET-034i、MET-067i 和 MET-PYYi。
Metsera Inc簡介
公司代碼MTSR
公司名稱Metsera Inc
上市日期Jan 31, 2025
CEOMr. Christopher Whitten Bernard
員工數量74
證券類型Ordinary Share
年結日Jan 31
公司地址3 World Trade Center
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編10007
電話12127846595
網址https://metsera.com/
公司代碼MTSR
上市日期Jan 31, 2025
CEOMr. Christopher Whitten Bernard
Metsera Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Paul L. Berns
Mr. Paul L. Berns
Independent Director
Independent Director
957.56K
--
Mr. Matthew Lang, J.D.
Mr. Matthew Lang, J.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Dr. Brian Hubbard, Ph.D.
Dr. Brian Hubbard, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Steven Marso, M.D.
Dr. Steven Marso, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
Independent Director
Independent Director
--
--
Dr. Clive A. Meanwell, M.D.
Dr. Clive A. Meanwell, M.D.
Executive Chairman of the Board, Founder
Executive Chairman of the Board, Founder
--
--
Mr. Christopher Whitten Bernard
Mr. Christopher Whitten Bernard
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher J. (Chris) Visioli
Mr. Christopher J. (Chris) Visioli
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
--
--
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Paul L. Berns
Mr. Paul L. Berns
Independent Director
Independent Director
957.56K
--
Mr. Matthew Lang, J.D.
Mr. Matthew Lang, J.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Dr. Brian Hubbard, Ph.D.
Dr. Brian Hubbard, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Steven Marso, M.D.
Dr. Steven Marso, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Dr. Joshua Pinto, Ph.D.
Dr. Joshua Pinto, Ph.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月25日 週一
更新時間: 8月25日 週一
持股股東
股東類型
持股股東
持股股東
佔比
ARCH Venture Partners
25.47%
Fidelity Management & Research Company LLC
14.97%
Validae Health, L.P
12.13%
Alphabet, Inc.
4.71%
Newpath Partners LP
4.63%
其他
38.09%
持股股東
持股股東
佔比
ARCH Venture Partners
25.47%
Fidelity Management & Research Company LLC
14.97%
Validae Health, L.P
12.13%
Alphabet, Inc.
4.71%
Newpath Partners LP
4.63%
其他
38.09%
股東類型
持股股東
佔比
Venture Capital
36.88%
Investment Advisor
32.29%
Corporation
16.76%
Investment Advisor/Hedge Fund
12.27%
Hedge Fund
2.47%
Individual Investor
0.91%
Research Firm
0.17%
Bank and Trust
0.06%
Pension Fund
0.03%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
173
88.61M
84.17%
+4.23M
2025Q2
133
95.51M
90.92%
+74.51M
2025Q1
104
95.08M
90.50%
+81.16M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
ARCH Venture Partners
26.82M
25.47%
+2.22M
+9.04%
Feb 03, 2025
Fidelity Management & Research Company LLC
15.76M
14.97%
+590.52K
+3.89%
Jun 30, 2025
Validae Health, L.P
12.77M
12.13%
--
--
Mar 31, 2025
Alphabet, Inc.
4.96M
4.71%
--
--
Jun 30, 2025
Newpath Partners LP
4.88M
4.63%
+4.88M
--
Jan 31, 2025
SB Global Advisers Ltd
4.82M
4.58%
--
--
Jun 30, 2025
MIC Capital Management UK LLP
4.54M
4.31%
--
--
Jun 30, 2025
VR Adviser, LLC
3.75M
3.56%
--
--
Jun 30, 2025
Wellington Management Company, LLP
3.43M
3.26%
+1.03M
+42.69%
Jun 30, 2025
Janus Henderson Investors
3.39M
3.22%
+482.50K
+16.61%
Jun 30, 2025
查看更多
持股ETF
更新時間: 10月2日 週四
更新時間: 10月2日 週四
機構名稱
佔比
Roundhill GLP-1 & Weight Loss ETF
4.21%
ALPS Medical Breakthroughs ETF
2.17%
Virtus LifeSci Biotech Clinical Trials ETF
0.79%
SPDR S&P Biotech ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
BNY Mellon US Small Cap Core Equity ETF
0.1%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
0.03%
ProShares Hedge Replication ETF
0.02%
Global X Russell 2000 ETF
0.02%
查看更多
Roundhill GLP-1 & Weight Loss ETF
佔比4.21%
ALPS Medical Breakthroughs ETF
佔比2.17%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.79%
SPDR S&P Biotech ETF
佔比0.16%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.1%
BNY Mellon US Small Cap Core Equity ETF
佔比0.1%
JPMorgan BetaBuilders US Small Cap Equity ETF
佔比0.03%
Invesco Russell 2000 Dynamic Multifactor ETF
佔比0.03%
ProShares Hedge Replication ETF
佔比0.02%
Global X Russell 2000 ETF
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
